Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,997 | 206 | 99.5% |
| Education | $14.16 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $655.13 | 48 | $0 (2023) |
| Novo Nordisk Inc | $622.64 | 46 | $0 (2023) |
| PFIZER INC. | $412.06 | 30 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $321.51 | 21 | $0 (2023) |
| Lilly USA, LLC | $212.37 | 15 | $0 (2023) |
| ABBVIE INC. | $165.67 | 8 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $135.98 | 8 | $0 (2020) |
| Amgen Inc. | $87.90 | 6 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $72.97 | 6 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $65.42 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13.86 | 1 | ABBVIE INC. ($13.86) |
| 2023 | $161.46 | 9 | Novo Nordisk Inc ($40.34) |
| 2022 | $842.34 | 54 | Novo Nordisk Inc ($223.34) |
| 2021 | $662.29 | 48 | PFIZER INC. ($150.18) |
| 2020 | $206.35 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($68.68) |
| 2019 | $844.38 | 60 | AstraZeneca Pharmaceuticals LP ($212.68) |
| 2018 | $245.00 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($76.24) |
| 2017 | $35.34 | 3 | PFIZER INC. ($35.34) |
All Payment Transactions
208 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/13/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: NEUROSCIENCE | ||||||
| 11/01/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: NEUROSCIENCE | ||||||
| 02/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Obesity | ||||||
| 02/06/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/30/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/27/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Inflammation | ||||||
| 01/18/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Diabetes | ||||||
| 01/12/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: VACCINES | ||||||
| 01/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: DIABETES | ||||||
| 01/06/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Diabetes | ||||||
| 12/16/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.94 | General |
| 12/15/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/05/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.27 | General |
| Category: Diabetes | ||||||
| 11/21/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $11.99 | General |
| 11/18/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Endocrinology | ||||||
| 11/18/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Endocrinology | ||||||
| 11/15/2022 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Neuroscience | ||||||
| 11/14/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Diabetes | ||||||
| 10/31/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: Inflammation | ||||||
| 10/30/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: DIABETES | ||||||
| 10/25/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: Diabetes | ||||||
| 10/24/2022 | PFIZER INC. | ELIQUIS (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/18/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Diabetes | ||||||
| 10/14/2022 | Lilly USA, LLC | EMGALITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: Neuroscience | ||||||
| 10/10/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.68 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 753 | 885 | $176,531 | $69,649 |
| 2022 | 18 | 907 | 1,039 | $189,240 | $81,531 |
| 2021 | 17 | 894 | 1,109 | $191,701 | $84,783 |
| 2020 | 20 | 961 | 1,131 | $190,027 | $73,069 |
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 223 | 332 | $80,676 | $25,894 | 32.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 140 | 140 | $34,720 | $16,987 | 48.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 31 | 31 | $16,430 | $8,443 | 51.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 87 | $14,964 | $5,001 | 33.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 51 | 51 | $7,469 | $3,655 | 48.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $5,724 | $2,161 | 37.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 66 | 67 | $3,868 | $1,916 | 49.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 12 | 12 | $3,816 | $1,883 | 49.3% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 28 | 28 | $2,240 | $1,029 | 45.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 22 | 28 | $2,800 | $1,016 | 36.3% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 31 | 31 | $1,736 | $886.60 | 51.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 37 | 43 | $1,333 | $409.36 | 30.7% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 17 | 17 | $755.00 | $368.25 | 48.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 249 | 363 | $77,385 | $27,037 | 34.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 165 | 165 | $37,904 | $20,379 | 53.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 25 | 25 | $11,970 | $6,965 | 58.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 84 | 95 | $13,820 | $5,364 | 38.8% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 18 | 19 | $6,316 | $2,972 | 47.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $9,364 | $2,832 | 30.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 40 | 40 | $5,516 | $2,732 | 49.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 17 | 17 | $5,466 | $2,716 | 49.7% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 14 | 14 | $4,428 | $2,226 | 50.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 65 | 65 | $3,532 | $1,754 | 49.7% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 13 | 13 | $2,795 | $1,723 | 61.6% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 29 | 29 | $2,320 | $1,034 | 44.6% |
About Dr. Robert Learch, DO
Dr. Robert Learch, DO is a Internal Medicine healthcare provider based in Paducah, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2012. The National Provider Identifier (NPI) number assigned to this provider is 1174882658.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Learch, DO has received a total of $3,011 in payments from pharmaceutical and medical device companies, with $13.86 received in 2024. These payments were reported across 208 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,997).
As a Medicare-enrolled provider, Learch has provided services to 3,515 Medicare beneficiaries, totaling 4,164 services with total Medicare billing of $309,032. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Paducah, KY
- Active Since 05/03/2012
- Last Updated 12/10/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1174882658
Products in Payments
- JARDIANCE (Drug) $521.78
- Ozempic (Drug) $292.80
- ELIQUIS (Drug) $224.54
- FARXIGA (Drug) $206.01
- Rybelsus (Drug) $158.16
- XIFAXAN (Drug) $120.81
- TRULICITY (Drug) $111.85
- STIOLTO RESPIMAT (Drug) $96.93
- PREVNAR 20 (Biological) $91.66
- VRAYLAR (Drug) $83.91
- ENTRESTO (Drug) $65.42
- MYRBETRIQ (Drug) $58.55
- Otezla (Drug) $58.21
- Tresiba (Drug) $48.23
- JANUVIA (Drug) $47.75
- PREVNAR - 13 (Biological) $47.03
- Dexcom G6 Transmitter (Medical Supply) $45.96
- RYBELSUS (Drug) $45.73
- XARELTO (Drug) $45.21
- EMGALITY (Drug) $45.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Paducah
Dr. Martin Rains, M.d, M.D
Internal Medicine — Payments: $48,397
Dr. Wederson Claudino, Md, MD
Internal Medicine — Payments: $29,178
Jacob Elrod, Md, MD
Internal Medicine — Payments: $24,847
Michael Faulkner, M.d, M.D
Internal Medicine — Payments: $16,943
Ryan Frazine, M.d, M.D
Internal Medicine — Payments: $10,062
Dr. Van Meeks, M.d, M.D
Internal Medicine — Payments: $7,786